

SIGN 116: Management of diabetes

Review report

Date	Update request	Decision	Status	Description
23/09/2013	New guidance from WHO indicates that Hba1c should be considered as a definitive diagnostic tool for diabetes.	Update	Published May 2014	Section 1.3 updated to reflect the WHO guidance on HbA1c as a diagnostic test for diabetes and UK expert position statement covering implementation of the test.
25/04/2012	Evidence has emerged on intravitreal anti-VEGF and steroid drugs for diabetic macular oedema to update section 10.3.4. The anti-VEGF drugs include ranibizumab, bevacizumab and pegaptanib. The steroids now include fluocinolone with dexamethasone (Ozurdex) upcoming.	No update as new evidence does not change recommendation	n/a	
24/09/2010	Marketing authorisation for all rosiglitazone-containing medicines suspended across the European Union.	Update	Published May 2011	Sections 6.5.6 and 6.11 updated to remove recommendations for, and include safety advice from European Medicines Agency and U.S. Food and Drug Administration on cardiovascular risks of, rosiglitazone and rosiglitazone-containing medicines.